נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Oral Immunotherapy for Children with a High Threshold Peanut Allergy
Year:
2022
Source of publication :
Annals of Allergy
Authors :
Hovav, Ran H.
;
.
Volume :
Co-Authors:

Soad Haj Yahia
Diti Machnes-Maayan
Shirly Frizinsky
Ramit Maoz-Segal
Irena Offenganden
Ron S Kenett
Nancy Agmon-Levin
Ran Hovav
Mona I Kidon

Facilitators :
From page:
0
To page:
0
(
Total pages:
1
)
Abstract:

Background: Between 25%-30% of peanut allergic (PA) children, have a relatively high threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates.

Objective: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol, in a group of children with HTPA.

Methods: PA children with an SMTD higher than 100mg, were placed on a 40 week OIT protocol of either 300 mg/day of PP or 100 mg/day for 20 weeks followed by 300 mg/day for 20 weeks. A repeat open peanut food challenge was performed after 40 weeks of treatment and at a 6 months follow-up visit. After the 40 week challenge, all children received a maintenance dose of 2gr PP 3 times a week.

Results: 28 children with HTPA were enrolled, 56% boys, 89% younger than 6yo, with a mean SMTD of 304 mg (95% CI 229-378). All were placed on the OIT protocol described above. Two children were not compliant and 3 had allergic reactions at home on the dose previously tolerated in clinic, 23 completed the 40 week protocol, All were able to consume 2 gr of PP. The mean tolerated dose at the 6 months follow-up, was 8gr. This enabled most children age appropriate dietary inclusion of peanut containing products.

Conclusion: In children with high threshold PA, a simple, fixed dose OIT can be both safe and efficacious.

Note:
Related Files :
anaphylaxis
child
diagnosis
Eliciting Dose
Food allergy
immunoglobulin E
Threshold
Show More
Related Content
More details
DOI :
10.1016/j.anai.2022.05.001
Article number:
0
Affiliations:
Database:
PubMed
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
59035
Last updated date:
25/05/2022 17:10
Creation date:
25/05/2022 16:02
Scientific Publication
Oral Immunotherapy for Children with a High Threshold Peanut Allergy

Soad Haj Yahia
Diti Machnes-Maayan
Shirly Frizinsky
Ramit Maoz-Segal
Irena Offenganden
Ron S Kenett
Nancy Agmon-Levin
Ran Hovav
Mona I Kidon

Oral Immunotherapy for Children with a High Threshold Peanut Allergy .

Background: Between 25%-30% of peanut allergic (PA) children, have a relatively high threshold peanut allergy (HTPA), with a single maximal tolerated dose (SMTD) higher than 100 mg of peanut protein (PP). However, this threshold may decrease with time, age, exercise, illness, sleep deprivation, and other covariates.

Objective: To explore the feasibility of a simplified oral immunotherapy (OIT) protocol, in a group of children with HTPA.

Methods: PA children with an SMTD higher than 100mg, were placed on a 40 week OIT protocol of either 300 mg/day of PP or 100 mg/day for 20 weeks followed by 300 mg/day for 20 weeks. A repeat open peanut food challenge was performed after 40 weeks of treatment and at a 6 months follow-up visit. After the 40 week challenge, all children received a maintenance dose of 2gr PP 3 times a week.

Results: 28 children with HTPA were enrolled, 56% boys, 89% younger than 6yo, with a mean SMTD of 304 mg (95% CI 229-378). All were placed on the OIT protocol described above. Two children were not compliant and 3 had allergic reactions at home on the dose previously tolerated in clinic, 23 completed the 40 week protocol, All were able to consume 2 gr of PP. The mean tolerated dose at the 6 months follow-up, was 8gr. This enabled most children age appropriate dietary inclusion of peanut containing products.

Conclusion: In children with high threshold PA, a simple, fixed dose OIT can be both safe and efficacious.

Scientific Publication
You may also be interested in